3 Undervalued S&P 500 Dividend Stocks Present Buying Opportunity Amid Market Divergence
The S&P 500's rally has left select dividend stocks behind, with Merck (MRK) emerging as a compelling contrarian play. Shares of the pharmaceutical giant have tumbled 39% from their peak, weighed down by Keytruda patent cliffs and Gardasil demand concerns in China. Yet the market may be overlooking Merck's pipeline potential—MK-1022 shows particular promise in NSCLC despite crowded competition.
Income investors are presented with rare discounts across healthcare and defensive sectors. This divergence mirrors crypto markets, where blue-chip assets like BTC and ETH consolidate while speculative tokens oscillate. The disciplined approach remains consistent: accumulate quality during weakness.